```html

Zollinger‑Ellison Gastric Ulcers

What is Zollinger‑Ellison Gastric Ulcers?

Zollinger‑Ellison syndrome (ZES) is a rare hormonal disorder in which one or more tumors called gastrinomas form in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach’s acid‑producing cells. The resulting hyper‑secretion of gastric acid overwhelms the protective mucus layer of the stomach and duodenum, leading to the development of gastric ulcers that are often multiple, deep, and resistant to standard ulcer therapy.

While “Zollinger‑Ellison gastric ulcer” is not a separate disease, it describes the ulcerative lesions that arise as a direct consequence of ZES. Understanding the underlying syndrome is essential because the management of the ulcers differs from typical peptic‑ulcer disease.

Source: Mayo Clinic; CDC

Common Causes

Gastric ulcers in the context of ZES are driven by the overproduction of gastrin, but several other conditions can either mimic the presentation or coexist with ZES, worsening ulcer formation. The most frequent contributors include:

• Gastrinomas (Zollinger‑Ellison tumors) – the primary cause of hyper‑gastrinemia.
• Multiple endocrine neoplasia type 1 (MEN‑1) – up to 25 % of patients with gastrinomas have MEN‑1.
• Helicobacter pylori infection – can aggravate ulcer severity when combined with high acid output.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or aspirin – damage the gastric mucosa and potentiate ulcer formation.
• Chronic use of proton‑pump inhibitors (PPIs) after abrupt discontinuation – rebound acid hyper‑secretion may unmask underlying ZES.
• Hyperparathyroidism – often part of MEN‑1 and can increase calcium‑stimulated gastrin release.
• Genetic mutations (e.g., MEN1 gene, CDKN1B) – predispose to gastrinoma development.
• Smoking – stimulates gastrin release and reduces mucosal blood flow.
• Alcohol excess – irritates the gastric lining and may increase acid output.
• Stress‑related mucosal disease – severe physiological stress (e.g., burns, trauma) can worsen acid‑related injury.

Associated Symptoms

Because the ulcers are produced by massive acid secretion, patients often present with a characteristic cluster of symptoms that differ from typical peptic‑ulcer disease:

• Severe, gnawing epigastric pain that may improve with food but recurs 1–3 hours after meals (“acid rebound”).
• Frequent diarrhea or watery stools caused by acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty, foul‑smelling stools) indicating malabsorption.
• Unexplained weight loss despite normal or increased appetite.
• Recurrent vomiting, sometimes with blood (hematemesis) or coffee‑ground material.
• Upper gastrointestinal bleeding leading to melena (black, tarry stools).
• Abdominal bloating and early satiety.
• In rare cases, gastric outlet obstruction due to large ulcerative lesions.

Symptoms often appear earlier in life (median age 45) compared with ordinary peptic‑ulcer disease.

When to See a Doctor

Prompt medical evaluation is crucial when any of the following occur:

• Persistent epigastric pain lasting >2 weeks despite over‑the‑counter antacids.
• Vomiting blood, passing black stools, or noticing blood in the vomitus.
• Unexplained weight loss >5 % of body weight within 3 months.
• Severe diarrhea (>3 watery stools per day) or signs of dehydration.
• Sudden onset of severe, worsening abdominal pain (possible perforation).
• Family history of MEN‑1, pancreatic neuroendocrine tumors, or gastrinomas.

If you have any of these signs, schedule an appointment with a gastroenterologist or an endocrinologist without delay.

Diagnosis

Diagnosing Zollinger‑Ellison gastric ulcers involves confirming both the presence of ulcer disease and the underlying gastrin‑secreting tumor.

1. Laboratory Evaluation

• Fasting serum gastrin level – Levels >1000 pg/mL are highly suggestive of gastrinoma; intermediate levels require stimulation testing.
• Secretin stimulation test – Paradoxical rise in gastrin after secretin administration confirms gastrinoma.
• Basic metabolic panel to assess electrolytes, calcium (hypercalcemia may point to MEN‑1), and renal function.

2. Imaging Studies

• Endoscopic examination (EGD) – Direct visualization of multiple, large, deep gastric/duodenal ulcers; biopsies rule out malignancy.
• Endoscopic ultrasound (EUS) – High‑resolution imaging to locate small pancreatic or duodenal tumors.
• Multiphasic contrast CT or MRI of the abdomen – Detects primary gastrinoma and metastatic disease (especially in the liver).
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – Highly sensitive for neuroendocrine tumors.

3. Additional Tests

• Upper gastrointestinal series (barium swallow) – rarely needed now but may show ulcer crater morphology.
• Genetic testing for MEN1 mutations if a hereditary syndrome is suspected.

Diagnostic Criteria (NIH Consensus)

1. Fasting serum gastrin >1000 pg/mL, or <1000 pg/mL with a positive secretin test.
2. Evidence of acid hyper‑secretion (pH <2 in the gastric antrum on 24‑hour pH monitoring).
3. Imaging confirming a gastrinoma (≥0.5 cm) or metastatic disease.

Treatment Options

Treatment of Zollinger‑Ellison gastric ulcers is two‑pronged: control acid hyper‑secretion and address the gastrinoma.

Medical Management

• Proton‑pump inhibitors (PPIs) – High‑dose regimens (e.g., omeprazole 40–80 mg daily or equivalent) are first‑line to normalize gastric pH and promote ulcer healing. Doses may be titrated based on symptom control and gastric pH monitoring.
• Histamine‑2 receptor antagonists (H2 blockers) – Typically used only as adjuncts; PPIs are superior for ZES.
• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin release and can shrink tumor size in some patients, especially when surgery isn’t feasible.
• Antibiotic therapy for H. pylori – If infection is present, a standard triple or quadruple regimen (clarithromycin‑based or bismuth‑based) is indicated.
• Supportive care – Rehydration, electrolyte replacement, and nutritional support for patients with malabsorption or weight loss.

Surgical Options

• Enucleation or pancreaticoduodenectomy – Preferred when the gastrinoma is localized and resectable; offers potential cure.
• Liver metastasectomy – Considered if metastases are limited and the patient’s functional status permits.
• Debulking surgery – Reduces tumor burden when complete resection is impossible; often combined with medical therapy.

Targeted and Systemic Therapies

• Everolimus or sunitinib – FDA‑approved for progressive, well‑differentiated pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – Uses radiolabeled somatostatin analogues (e.g., 177Lu‑DOTATATE) for metastatic disease.
• Cytotoxic chemotherapy – Reserved for high‑grade or rapidly progressive tumors.

Home & Lifestyle Measures

• Take PPIs exactly as prescribed; never skip doses.
• Avoid NSAIDs, aspirin, and alcohol, all of which increase ulcer risk.
• Eat small, frequent meals rather than large meals that stimulate extra acid production.
• Stay hydrated; replace fluids lost through diarrhea.
• Consider a low‑fat diet to lessen steatorrhea while awaiting tumor treatment.

Prevention Tips

While the underlying gastrinoma cannot be prevented, certain measures can reduce ulcer complications and support overall gastrointestinal health:

• Do not self‑medicate with over‑the‑counter antacids for persistent pain; seek professional evaluation early.
• Limit or eliminate NSAID use; if needed, use the lowest effective dose with a protective PPI.
• Screen for and eradicate H. pylori infection, especially in patients with a family history of ulcer disease.
• Maintain a healthy weight and avoid smoking, both of which increase gastrin secretion.
• For those with known MEN‑1 mutations, undergo regular surveillance (annual hormone panels and imaging) to detect gastrinomas early.
• Stay up‑to‑date with vaccinations (e.g., hepatitis B) if undergoing immunosuppressive therapy for advanced disease.

Emergency Warning Signs

Key Take‑aways

Zollinger‑Ellison gastric ulcers are a manifestation of an underlying gastrin‑producing tumor that leads to extreme gastric acidity. Early recognition, aggressive acid suppression, and targeted treatment of the gastrinoma are essential for healing ulcers and preventing serious complications such as bleeding or perforation. If you have persistent upper‑abdominal pain, unexplained weight loss, or any of the emergency warning signs above, seek medical care promptly.

References:

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org. Accessed June 2026.
2. National Institutes of Health (NIH). Consensus guidelines for the management of neuroendocrine tumors. PubMed. 2020.
3. Cleveland Clinic. Gastrinoma (Zollinger‑Ellison syndrome) treatment. https://my.clevelandclinic.org. Accessed June 2026.
4. World Health Organization. WHO classification of tumors of the digestive system (2022). WHO.
5. American College of Gastroenterology. ACG clinical guideline: management of peptic ulcer disease. https://gi.org. 2021.

```